Drug Safety Inboxes Need Speed Without Losing the Thread

Pharmacovigilance is not a software genre. It is a deadline sport played with forwarded clinician notes, lab PDFs, and threads that start with “FYI—possible event.” FDA’s FAERS public dashboard and Q&A explain how adverse event narratives flow from health professionals and manufacturers into reporting pathways that often begin as email (<a href="https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard" target="_blank" rel="noopener noreferrer">FDA FAERS dashboard</a>). Postmarketing safety reporting guidance reinforces timelines that reward triage speed without forgiving sloppy documentation (<a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-safety-reporting-human-drug-and-biological-products" target="_blank" rel="noopener noreferrer">FDA postmarketing safety reporting</a>). EMA pharmacovigilance materials stress signal management with traceable medical review (<a href="https://www.ema.europa.eu/en/human-regulatory-overview/research-development-pharmacovigilance/pharmacovigilance" target="_blank" rel="noopener noreferrer">EMA pharmacovigilance</a>). ICH E2B defines how individual case safety reports move between regulators—your inbox is still where the story starts (<a href="https://database.ich.org/sites/default/files/E2B%28R3%29_Guideline.pdf" target="_blank" rel="noopener noreferrer">ICH E2B guideline PDF</a>). Nature Medicine commentary on real-world evidence highlights growing data volumes as decentralized monitoring expands (<a href="https://www.nature.com/articles/s41591-021-01533-7" target="_blank" rel="noopener noreferrer">Nature Medicine on real-world evidence</a>). The same journal’s LLM-in-medicine primer pairs technical benchmarks with workflow ethics—exactly the tension PV teams live in (<a href="https://www.nature.com/articles/s41591-023-02448-8" target="_blank" rel="noopener noreferrer">Nature Medicine on LLMs in medicine</a>).

Medical reviewers should not be fighting Microsoft Word at 11 p.m. because the first draft took too long. They should be checking facts, timelines, and clinical plausibility. Models can assist drafting; humans must authorize submission.

Agents that sit beside the case thread

via.email offers mailable specialists—each reply from an LLM with a fixed expert prompt—so PV teams compress repetitive drafting without adopting another portal. via.email does not access your mailbox or send on your behalf; you forward or email content in-thread.

• Draft Safety Notice — draft.safety.notice@via.email
• Summarize Contract Obligations — summarize.contract.obligations@via.email
• Extract Action Items — extract.action.items@via.email
• Build Compliance Evidence — build.compliance.evidence@via.email
• Distill to Three — distill.to.three@via.email

Full directory: https://www.via.email/agents. Tier details: https://www.via.email/pricing.

Practical next step

Route repetitive narrative drafting to Draft Safety Notice with a QC checklist in the body. Use Extract Action Items on long clinical emails before medical review. Keep QC sign-off human—this is assistance inside SMTP, not autonomous case filing.

Related reading

Regulated correspondence already behaves like evidence—see clinical coordinators and the compliance thread. Legal teams face the same PDF-to-thread loop we describe in contract deadlines hiding in attachments. When audit asks for proof-by-email, internal audit’s PBC pattern rhymes with PV reconstruction.

Speed without traceability is how companies buy regulatory pain. Keep the thread, add drafting help, and let physicians own the signature.